---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-067569"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:51:30.337770+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics initiates strategic alternatives review, hires Piper Sandler

## Summary
- Feb 24, 2026: Werewolf (HOWL) announces exploration of strategic alternatives including sale, merger, or licensing.
- Hired Piper Sandler & Co. as exclusive financial advisor to assist in the strategic evaluation.
- CEO Dan Hicklin cites INDUKINE and INDUCER platforms and clinical-stage candidates as core assets.
- No defined timeline; company will not disclose further unless board approves specific action.

## SEC filing metadata
- accession: 0001193125-26-067569
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312526067569/0001193125-26-067569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312526067569/d808115d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-067569
- JSON: https://secwatch.observer/filing/0001193125-26-067569.json
- Plain text: https://secwatch.observer/filing/0001193125-26-067569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.